There is another approach of ACT by identifying RAS‐mutant specific antigens for the treatment of NRASmut melanoma and have some breakthroughs in the treatment of NSCLC with KRAS mutation [487]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.